McCowan Peter M, Asuni Ganiyu, Van Uytven Eric, VanBeek Timothy, McCurdy Boyd M C, Loewen Shaun K, Ahmed Naseer, Bashir Bashir, Butler James B, Chowdhury Amitava, Dubey Arbind, Leylek Ahmet, Nashed Maged
Medical Physics Department, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
Medical Physics Department, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):1077-1084. doi: 10.1016/j.ijrobp.2017.01.227. Epub 2017 Feb 2.
To report findings from an in vivo dosimetry program implemented for all stereotactic body radiation therapy patients over a 31-month period and discuss the value and challenges of utilizing in vivo electronic portal imaging device (EPID) dosimetry clinically.
From December 2013 to July 2016, 117 stereotactic body radiation therapy-volumetric modulated arc therapy patients (100 lung, 15 spine, and 2 liver) underwent 602 EPID-based in vivo dose verification events. A developed model-based dose reconstruction algorithm calculates the 3-dimensional dose distribution to the patient by back-projecting the primary fluence measured by the EPID during treatment. The EPID frame-averaging was optimized in June 2015. For each treatment, a 3%/3-mm γ comparison between our EPID-derived dose and the Eclipse AcurosXB-predicted dose to the planning target volume (PTV) and the ≥20% isodose volume were performed. Alert levels were defined as γ pass rates <85% (lung and liver) and <80% (spine). Investigations were carried out for all fractions exceeding the alert level and were classified as follows: EPID-related, algorithmic, patient setup, anatomic change, or unknown/unidentified errors.
The percentages of fractions exceeding the alert levels were 22.6% for lung before frame-average optimization and 8.0% for lung, 20.0% for spine, and 10.0% for liver after frame-average optimization. Overall, mean (± standard deviation) planning target volume γ pass rates were 90.7% ± 9.2%, 87.0% ± 9.3%, and 91.2% ± 3.4% for the lung, spine, and liver patients, respectively.
Results from the clinical implementation of our model-based in vivo dose verification method using on-treatment EPID images is reported. The method is demonstrated to be valuable for routine clinical use for verifying delivered dose as well as for detecting errors.
报告在31个月期间为所有立体定向体部放射治疗患者实施的体内剂量测定计划的结果,并讨论临床应用体内电子射野影像装置(EPID)剂量测定的价值和挑战。
2013年12月至2016年7月,117例立体定向体部放射治疗-容积调强弧形治疗患者(100例肺部、15例脊柱和2例肝脏)接受了602次基于EPID的体内剂量验证。一种开发的基于模型的剂量重建算法通过对治疗期间EPID测量的初始注量进行反投影来计算患者的三维剂量分布。2015年6月对EPID帧平均进行了优化。对于每次治疗,在我们基于EPID得出的剂量与Eclipse AcurosXB预测的计划靶体积(PTV)及≥20%等剂量体积的剂量之间进行3%/3毫米γ比较。警戒水平定义为γ通过率<85%(肺部和肝脏)和<80%(脊柱)。对所有超过警戒水平的分次进行调查,并分类如下:与EPID相关、算法、患者摆位、解剖结构改变或未知/未识别的误差。
帧平均优化前肺部超过警戒水平的分次百分比为22.6%,帧平均优化后肺部为8.0%,脊柱为20.0%,肝脏为10.0%。总体而言,肺部、脊柱和肝脏患者的计划靶体积γ平均通过率分别为90.7%±9.2%、87.0%±9.3%和91.2%±3.4%。
报告了我们基于模型的使用治疗中EPID图像的体内剂量验证方法的临床实施结果。该方法被证明对于验证实际 delivered dose 以及检测误差在常规临床应用中具有价值。 (注:原文中“delivered dose”未翻译完整,可能是“实际给予剂量”之类的意思,需结合更完整的医学语境准确理解)